GNH USA

Europe — EMA

Myfortic (Mycophenolic Acid)

GNH USA supplies Myfortic (Mycophenolic Acid), a immunosuppressant for prevention of acute rejection in kidney, heart and liver transplants.

Request sourcing

1
Pack/s

What is Mycophenolic Acid?

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral tablet for oral use. It is used to prevent acute rejection in organ transplantation, including kidney, heart and liver transplants, by suppressing immune cell proliferation.

GNH USA supplies Myfortic as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

What is Mycophenolic Acid used for?

Myfortic is an antimetabolite immunosuppressant that acts on lymphocyte proliferation to reduce organ rejection risk.

Renal transplantation: helps prevent acute graft rejection in kidney recipients. Heart transplantation: reduces the likelihood of acute rejection after heart transplant. Liver transplantation: supports maintenance of graft function by limiting immune‑mediated damage.

What are the side effects of Mycophenolic Acid?

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Abdominal pain - Headache - Tremor

Serious or Rare Side Effects: - Severe infections - Leukopenia or anemia - Malignancies such as lymphoma - Progressive multifocal leukoencephalopathy (PML) - Hepatic injury - Life‑threatening hypersensitivity reactions

What precautions apply to Mycophenolic Acid?

Patients receiving Myfortic should be monitored closely for safety concerns.

Monitor blood counts: watch for leukopenia, anemia, or thrombocytopenia. Assess renal function: adjust therapy if kidney function declines. Check liver enzymes: detect potential hepatic toxicity. Avoid live vaccines: immunosuppression can increase infection risk. Use effective contraception: drug may be teratogenic. Store at ambient temperature: keep in original pack, protect from moisture.

What does Mycophenolic Acid interact with?

Myfortic can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of infection. - Rifampin and other strong CYP3A4 inducers: reduce mycophenolate exposure. - Azathioprine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - ACE inhibitors: heightened renal adverse effects. - NSAIDs: may exacerbate renal impairment. - Warfarin: potential alteration of INR values.

Frequently asked questions

What is Myfortic used for?+
Myfortic is a brand name for mycophenolate sodium, used as an immunosuppressant to prevent acute organ rejection in patients who have undergone kidney, heart, or liver transplantation. It works by inhibiting lymphocyte proliferation, thereby reducing the immune response that can damage the transplanted organ. The medication is prescribed by transplant physicians as part of a maintenance regimen.
How does Mycophenolic Acid work?+
Mycophenolic Acid selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. By blocking this pathway, the drug reduces the production of DNA and RNA in T‑ and B‑cells, suppressing their proliferation and activity. This targeted immunosuppression helps to prevent the immune system from attacking a newly transplanted organ.
What is the usual dose of Myfortic?+
The specific dose of Myfortic is determined by the prescribing physician based on the patient’s transplant type, body weight, renal function, and concomitant medications. Dosing is individualized and may be adjusted over time to achieve the desired immunosuppressive effect while minimizing adverse reactions. Patients should follow the exact regimen provided by their healthcare professional and not alter the dose on their own.
Is Myfortic safe during pregnancy or breastfeeding?+
The safety of Myfortic (mycophenolate) during pregnancy and lactation is not well established, and it is generally classified as contraindicated for use in pregnant women because of potential teratogenic effects. Women of child‑bearing potential should use effective contraception while taking the drug and for a defined period after discontinuation. Breastfeeding is also discouraged, as the medication can be excreted in milk and affect the infant.
How do I order Myfortic from GNH USA?+
To place an order for Myfortic, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity and providing institutional or trade credentials. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, and will respond with pricing, availability, shipping details (including any temperature‑controlled requirements), and the necessary import documentation to complete the purchase.
How does Myfortic compare with other antimetabolite immunosuppressants?+
Myfortic (mycophenolate sodium) is an antimetabolite that offers a more favorable gastrointestinal tolerability profile compared with mycophenolate mofetil, its counterpart, due to its delayed‑release formulation. Both agents share the same mechanism of IMPDH inhibition, but Myfortic may be preferred in patients who experience significant nausea or vomiting with other formulations. Choice of therapy depends on individual patient response, side‑effect tolerance, and physician preference.
What are the recommended storage conditions for Myfortic?+
Myfortic tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and avoid storing the medication in bathrooms or near heat sources. Do not freeze the tablets, and discard any product that appears discoloured or damaged.
How is Myfortic administered?+
Myfortic is taken orally, usually as whole tablets, with or without food as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not chewed, crushed, or split unless specifically instructed. Consistent timing each day helps maintain stable blood levels, and patients should follow the dosing schedule provided by their transplant team.
What are the most serious risks associated with Myfortic?+
The most serious risks of Myfortic include severe infections due to immunosuppression, hematologic abnormalities such as leukopenia or anemia, and an increased risk of certain malignancies, including lymphomas and skin cancers. Liver injury and progressive multifocal leukoencephalopathy (PML) are rare but potentially fatal complications. Patients should be monitored regularly for signs of infection, blood count changes, and any new skin lesions.
Who should not use Myfortic?+
Myfortic is contraindicated in individuals with known hypersensitivity to mycophenolate sodium or any of its excipients. It should also be avoided in patients with active, uncontrolled infections, severe hepatic impairment, or those receiving live vaccines. Pregnant women and breastfeeding mothers are advised not to use the drug due to potential fetal and infant harm. Clinical judgment is required to assess suitability for each patient.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Mycophenolic Acid
Route
Oral Use
Manufacturer
Sia Novartis Baltics
Origin
EU

Related products